Alimera “Paladin” M-01-15-004

Status: Ongoing, but not recruiting participants

ClinicalTrials.gov Identifier: NCT02424019

Alimera “Paladin”: A phase 4 safety study of IOP Signals in patients treated with Iluvien (Fluocinolone Acetonide Intravitreal Implant) 0.19 MG

Condition: Diabetic Macular Edema (DME)

Study Type: Interventional

Duration: 36 Months

Eligibility:

  • Ages: Child, Adult, Senior
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information on this study, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.